Navigation Links
Are intravenous treatments safe? New research raises doubts
Date:8/31/2009

German scientists have identified a serious and previously misunderstood contaminant that brings the safety and efficacy of intravenous treatments into question. In a report published in the September 2009 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org), they show how a common intravenous treatment used to boost blood pressure in ailing patients also contains substances called "advanced glycation end products," which trigger inflammation. These substances result from reactions that occur among the various proteins (called "posttranslational modification") within the intravenous fluid after it has been formulated for use. This study directly challenges today's prevalent belief that advanced glycation end products are not contaminants.

"Improving the quality of infusion solutions by accounting for posttranslational modification of proteins could lead to better clinical outcomes for patients, such as those treated solutions containing albumin," said Angelika Bierhaus, senior scientist and co-study author from the University of Heidelberg in Germany.

To make their discovery, Bierhaus and colleagues detected advanced glycation end products in several currently available albumin infusion solutions and injected separate groups of mice with solutions containing both high and low amounts of this substance. The mice receiving the high levels of advanced glycation end products experienced significantly higher inflammation and death rates than the mice receiving solutions with low levels of advanced glycation end products. This suggests that screening infusion solutions for posttranslational protein modifications and then removing the compounds may improve patient outcomes, especially treatments requiring albumin infusions.

"It is always difficult to learn that what was once thought safe might have more risk than previously appreciated, especially when it relates to treatments meant to save lives," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "This discovery, however, should allow manufacturers to improve the quality, tolerability and safety of a number of clinical products."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
2. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
3. Most Important Factors Driving Usage of Antibiotics in the ICU Setting are Availability in Intravenous Formulation, Activity Against Key Gram Negative Pathogens, Drug Interactions and Bactericidal Activity
4. New form of intravenous iron treats anemia in chronic kidney disease patients on dialysis
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin
7. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
8. Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
9. Drug-free treatments offer hope for older people in pain
10. Updated Brochure on Gynecologic Cancer Treatments Now Available
11. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , ... May 04, 2016 , ... ... brand will provide the playing surface for the 2016 NCAA Men’s ... installed today for the men’s volleyball championship to be held May 5-7 at ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... provider serving families of Camas and Vancouver, WA, has announced the latest ... the National Breast Cancer Foundation and their Mammography Program, which provides free ...
(Date:5/4/2016)... ... 2016 , ... Level 10 Head Over Heels Athletic Arts’ gymnast Alessandra Brovedani ... Arizona for the fall of 2019. , After a handful of college visits, ... GymCats came from her connection with the coaching staff and the excitement surrounding Wildcat ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Todd Rider's research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven ... that starts on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for ...
(Date:5/4/2016)... ... May 04, 2016 , ... Olshan Properties ... real estate proudly announced that its service-based charitable program, Olshan Outreach, successfully raised ... will continue Olshan Properties’ annual philanthropic tradition in 2016 with the ‘Fight Against ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... , May 2, 2016 Leading Economies with Fastest ... 10.2 Côte d,Ivoire 8.6 Uzbekistan 8 Ireland 7.8 India 7.3, , ... BRICS nations , which comprises of Brazil , ... and South Africa , registered the fastest GDP growth ... in China , recession in Brazil ...
(Date:5/2/2016)... Mass. , May 2, 2016  While nearly ... that osteoporosis can have on their health, only about ...   according to the results of a new survey ... To mark the start of National Osteoporosis Month, Hologic ... health, which affects nearly 56 million Americans. ...
Breaking Medicine Technology: